Peer-reviewed veterinary case report
When to give bisphosphonates with radiation for dog bone cancer
By Hoddinott, Katie et al.·Published in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire·2020·Department of Clinical Studies (Hoddinott, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of timing of bisphosphonate administration on canine osteosarcoma cells undergoing radiation therapy.
- Species:
- dog
Plain-English summary
A study looked at how the timing of a medication called bisphosphonates affects dogs with osteosarcoma (a type of bone cancer) when combined with radiation therapy. It found that giving bisphosphonates after radiation therapy helped reduce the survival of cancer cells better than giving it before. While the overall health of the cancer cells didn't change significantly, the researchers suggest that waiting about 24 hours after radiation to give bisphosphonates might be the best approach to help slow down the cancer and improve pain relief.
People also search for: dog osteosarcoma treatment · bisphosphonates for dogs · radiation therapy for dog cancer
Abstract
The effects of radiation therapy may be potentiated by combining radiation therapy with secondary therapies. Clinically, radiation therapy has been combined with bisphosphonates for treatment of canine appendicular osteosarcoma for years. The objective of this study was to determine if the timing of administration of bisphosphonates in relation to radiation therapy alters clonogenic survival or cell viability of canine osteosarcoma cellsCanine osteosarcoma cells were treated before administration of radiation, concurrent with radiation, or after radiation. Reduction in clonogenic survival was identified when bisphosphonates were administered post-radiation compared with pre-radiation. No significant differences were identified for cell viability at any time points. Further investigation of the cellular effects of bisphosphonates on canine osteosarcoma cells is warranted. Consideration may be given to administering bisphosphonates 24 h after radiation to reduce replication of canine osteosarcoma cells and possibly prolong the analgesic effects of both treatments.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32801458/